Express Scripts has reached deals to cover two costly new cholesterol drugs and expects to spend roughly $750 million on them next year. Read More
POLITICO Group targeting drug costs enters early primary states By Brett… Read More
Across the country, Americans are finding the prices of the prescription drugs… Read More
Drug makers do not really want to explain how medicines are priced and, as a result, they have adopted an air of secrecy in which one cowboy can create havoc for an entire industry. Read More
As the 2016 presidential race heats up, prominent candidates are beginning to unveil comprehensive plans to address soaring prescription drug costs and the harmful impact their price tags have on Americans. Read More
Specialists in infectious disease are protesting a gigantic overnight increase in the price of a 62-year-old drug that is the standard of care for treating a life-threatening parasitic infection. Read More
"This latest health care price growth report indicates that spending on pricey prescription medications shows no sign of slowing down. When compared to other health care services, it is clear that high cost treatments continue to top the charts as a serious threat to the sustainability of our health care system and beyond." Read More
The pharmaceutical industry have, in recent years, focused on development of so-called specialty drugs and have priced them aggressively. These prices, such as the US$1,000 per pill price for the hepatitis C drug sofosbuvir, are alarming for patients, employers, insurers, and governments. Read More
Two powerful new drugs that can sharply lower cholesterol are vastly overpriced based on the value they provide, according to a new analysis by an independent organization that evaluates pharmaceutical costs. Read More
The hepatitis C drugs, which cured a vast majority of patients in clinical trials, are essentially a one-time cost. The cholesterol drugs, by contrast, will be taken for a lifetime. At these rates, the lifetime costs could be staggering. Read More
“With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market,” John Rother, leader of the Campaign for Sustainable Rx Pricing, said in a statement. Read More
"The approval of Repatha is another example of a breakthrough medication with a too high price tag. With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market.” Read More